Inhibitory effects of total saponin from Korean Red Ginseng on $[\text{Ca}^{2+}]_i$ mobilization through phosphorylation of cyclic adenosine monophosphate-dependent protein kinase catalytic subunit and inositol 1,4,5-trisphosphate receptor type I in human platelets

Jung-Hae Shin1,*, Hyuk-Woo Kwon1,*, Hyun-Jeong Cho2, Man Hee Rhee3, Hwa-Jin Park1,*

1 Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering, Inje University, Inje-ro, Gimhae-si, Gyeongsangnam-do, Korea
2 Department of Biomedical Laboratory Science, College of Medical Science, Konyang University, Gasuwon-dong, Seo-gu, Daejeon, Korea
3 Laboratory of Veterinary Physiology and Signaling, College of Veterinary Medicine, Kyungpook National University, Buk-gu, Daegu, Korea

Keywords: Ca$^{2+}$-mobilization inositol 1,4,5-trisphosphate receptor type I (Ser1756) phosphorylation Panax ginseng protein kinase A catalytic subunit (Thr197) phosphorylation total saponin from Korean Red Ginseng

Abstract

Background: Intracellular Ca$^{2+}$($[\text{Ca}^{2+}]_i$) is a platelet aggregation-inducing molecule. Therefore, understanding the inhibitory mechanism of $[\text{Ca}^{2+}]_i$ mobilization is very important to evaluate the antiplatelet effect of a substance. This study was carried out to understand the Ca$^{2+}$-antagonistic effect of total saponin from Korean Red Ginseng (KRG-TS).

Methods: We investigated the Ca$^{2+}$-antagonistic effect of KRG-TS on cyclic nucleotides-associated phosphorylation of inositol 1,4,5-trisphosphate receptor type I (IP3RI) and cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) in thrombin (0.05 U/mL)-stimulated human platelet aggregation.

Results: The inhibition of $[\text{Ca}^{2+}]_i$ mobilization by KRG-TS was increased by a PKA inhibitor (Rp-8-Br-cAMPS), which was more stronger than the inhibition by a cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG) inhibitor (Rp-8-Br-cGMPS). In addition, Rp-8-Br-cAMPS inhibited phosphorylation of PKA catalytic subunit (PKAc) (Thr197) by KRG-TS. The phosphorylation of IP3RI (Ser1756) by KRG-TS was very strongly inhibited by Rp-8-Br-cAMPS compared with that by Rp-8-Br-cGMPS. These results suggest that the inhibitory effect of $[\text{Ca}^{2+}]_i$ mobilization by KRG-TS is more strongly dependent on a cAMP/PKA pathway than a cGMP/PKG pathway. KRG-TS also inhibited the release of adenosine triphosphate and serotonin. In addition, only G-Rg3 of protopanaxadiol in KRG-TS inhibited thrombin-induced platelet aggregation.

Conclusion: These results strongly indicate that KRG-TS is a potent beneficial compound that inhibits $[\text{Ca}^{2+}]_i$ mobilization in thrombin–platelet interactions, which may result in the prevention of platelet aggregation-mediated thrombotic disease.

Copyright © 2015, The Korean Society of Ginseng. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Platelet aggregation is absolutely essential for the formation of a hemostatic plug when normal blood vessels are injured. However, the interactions between platelets and thrombin can also cause circulatory disorders, such as thrombosis, atherosclerosis, and myocardial infarction [1]. Accordingly, inhibition of the platelet–thrombin interaction might be a promising approach for the prevention of thrombosis. It is well-known that thrombin, a platelet agonist, stimulates platelet aggregation by binding to the Gq-
coupled proteinase-activated receptor, which is involved in activating phospholipase C-β (PLC-β). The activated PLC-β hydrolyzes phosphatidylinositol 4,5-bisphosphate to inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DG) [2–5]. Moreover, IP3 mobilizes cytosol-free Ca2+ ([Ca2+]i) from the dense tubular system by binding to the IP3 receptor type 1 (IP3RI). The increased [Ca2+]i activates both Ca2+/calmodulin-dependent phosphorylation of myosin light chain (20 kDa) and DG-dependent phosphorylation of pleckstrin (47 kDa) to induce granule secretion [adenosine triphosphate (ATP) secretion] and platelet aggregation [6,7]. The Ca2+−antagonistic effects of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are mediated through cAMP- and cGMP-dependent protein kinases (PKA and PKG, respectively), which phosphorylate the substrate protein IP3RI. The phosphorylation of IP3RI involves in inhibition of [Ca2+]i mobilization [8–10]. Therefore, understanding the mechanism of IP3RI phosphorilation is very useful for evaluating the Ca2+−antagonistic effect of various substances.

Ginseng, the root of Panax ginseng C.A. Meyer, has been used frequently in traditional Oriental medicine, and is known to possess various pharmacological effects such as anti-inflammatory, antioxidant, antitumor, antidiabetes, and antihypertotoxicity [11,12]. Recently, it has been reported that Korean Red Ginseng (KRG) also has an effect on cardiovascular disease, which is characterized by reduction in blood pressure and arterial stiffness by inhibition of Rho kinase activity [13], anticoagulation by prolonging prothrombin and activated partial thromboplastin times [14], endothelium relaxation by the nitric oxide–cGMP pathway [15], and inhibition of hypercholesterolemia-induced platelet aggregation [16]. In a previous report, it has been demonstrated that total saponin from KRG (KRG-TS) inhibits the production of thromboxane A2 (TXA2) in platelet-mediated thrombotic disease by suppressing the activities of cyclooxygenase-1 (COX-1) and thromboxane A2 synthase (TXAS) [17]. In addition, KRG-TS was reported to be involved in increasing the cAMP level and subsequent reduction of [Ca2+]i, mobilization in thrombin-induced rat platelet aggregation [18]. With regard to the effects of ginsenosides on platelet aggregation, it is well-known that ginsenoside Rg3 (G-Rg3) and its chemical derivatives (dihydropyrazinoinside Rg3 and ginsenoside Rp1) exhibit antplatelet effects by regulating the aggregation-inhibiting molecule (cAMP) and aggregation-stimulating molecules (extracellular kinase 2, tyrosine kinase-dependent phosphoproteins, TXA2, intracellular Ca2+, integrin αIIb/β3, etc.) [19–21]. In this study, to understand the inhibition of [Ca2+]i mobilization by KRG-TS [18], we investigated whether KRG-TS is involved in phosphorylation of IP3RI. We also examined which cyclic nucleotide of camp and cGMP participates in IP3RI phosphorylation to attenuate [Ca2+]i mobilization in thrombin-induced human platelet aggregation. In addition, our results showed that only G-Rg3 of protopanaxadiol in KRG-TS inhibited thrombin-induced platelet aggregation.

2. Materials and methods

2.1. Materials

KRG-TS was obtained from Korea Ginseng Corporation R&D Headquarters (Daejeon, Korea). Thrombin was purchased from Chrono-log Corporation (Havertown, PA, USA). The ATP assay kit was purchased from Biomedical Research Service Center (Buffalo, NY, USA). Serotonin enzyme-linked immunosorbent assay (ELISA) kit was purchased from Labor Diagnostika Nord GmbH & Co. (Nordhorn, Germany). Fura 2-acetoxymethyl [Fura 2-AM] and other reagents were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Anti-phospho-IP3RI (Ser1756), antiphospho-PKA catalytic subunit (PKAc; Thr197), antirabbit immunoglobulin G (IgG)−horseradish peroxidase conjugate (HRP), and lysis buffer were obtained from Cell Signaling (Beverly, MA, USA). Polyvinylidene difluoride (PVDF) membrane was obtained from GE Healthcare (Piscataway, NJ, USA). Enhanced chemiluminescence (ECL) solution was purchased from GE Healthcare (Chalfont St. Giles, Buckinghamshire, UK). Protopanaxadiol saponins [PPDSs; G-Ra1, G-Rb1, G-Rb2, G-Rb3, G- Rc, G-Rd, G-Rg3 (20R), G-Rg3 (20S), and G-Rh2 (20R)] and protopanaxatriol saponins [PTTs; G-Re, G-Rf, G-Rg1, G-Rg2 (20R), and G-Rh1 (20S)] were purchased from Ambro Institute (Daejeon, Korea).

2.2. Preparation of washed human platelets

Human−platelet-rich plasma (PRP) anticoagulated with acetic citrate−dextrose solution (0.8% citric acid, 2.2% sodium citrate, and 2.45% glucose) was obtained from Korean Red Cross Blood Center (Changwon, Korea). The PRP was centrifuged for 10 min at 125g to remove little red blood cells, and was centrifuged for another 10 min at 1,300 g to obtain the platelets. The platelets were washed two times with washing buffer (138mM NaCl, 2.7mM KCl, 12mM NaHCO3, 0.36mM NaH2PO4, 5.5mM glucose, and 1mM EDTA; pH 6.5). The washed platelets were then resuspended in suspension buffer (138mM NaCl, 2.7mM KCl, 12mM NaHCO3, 0.36mM NaH2PO4, 0.49mM MgCl2, 5.5mM glucose, and 0.25% gelatin; pH 6.9) to make up a final concentration of 5 × 10^8/mL. All of the aforementioned procedures were carried out at 25 °C to avoid platelet aggregation at low temperatures. The Korea National Institute for Bioethics Policy Public Institutional Review Board (Seoul, Korea) approved these experiments (PIRB12-072).

2.3. Measurement of platelet aggregation

Washed platelet (10^9/mL) were preincubated for 3 min at 37°C in the presence of 2mM exogenous CaCl2 with or without (KRG- TS, A-kinase/G-kinase inhibitor), and then stimulated with thrombin (0.05 U/mL) for 5 min. Aggregation was monitored using an aggregometer (Chrono-log Corporation) at a constant stirring speed of 1,000 rpm. Each aggregation rate was evaluated as an increase in light transmission. The suspension buffer was used as the reference (transmission 0). KRG- TS was dissolved in the platelet suspension buffer (pH 6.9).

2.4. Determination of cytosolic-free Ca2+^2+ 

PRP was incubated with 5µM Fura 2-AM at 37°C for 60 min. Because Fura 2-AM is light sensitive, the tube containing the PRP was covered with aluminum foil during loading. The Fura 2-loaded washed platelets were prepared using the aforementioned procedure and 10^8 platelets/mL were preincubated for 3 min at 37°C with or without KRG-TS in the presence of 2mM CaCl2, and then stimulated with thrombin (0.05 U/mL) for 5 min to evaluate [Ca2+]i. Fura 2 fluorescence was measured using a spectrofluorometer (SFM 25; BioTek Instruments, Milan, Italy) with an excitation wavelength that was changed every 0.5 s from 340 nm to 380 nm. The emission wavelength was set at 510 nm. The [Ca2+]i values were calculated using the method suggested by Schaeffer and Blaustein [22].

2.5. Determination of ATP and serotonin release

The washed platelets (10^9/mL) were preincubated for 3 min at 37°C with or without (KRG- TS, A-kinase/G-kinase inhibitor, A-kinase/G-kinase activator) in the presence of 2mM CaCl2, and then stimulated with thrombin (0.05 U/mL). The reaction was terminated and the mixture was centrifuged with 200xg at 4°C for 10 min. The supernatants were used for the ATP and serotonin release assays. ATP release was measured in a luminometer (GloMax 20/
Fig. 1. Effects of total saponin from Korean Red Ginseng (KRG-TS) on thrombin-induced human platelet aggregation. (A) Concentration threshold of thrombin on human platelet aggregation. (B) Effects of KRG-TS on resting human platelets. (C) Effects of KRG-TS on thrombin-induced human platelet aggregation. (D) Half-maximal inhibitory concentration (IC₅₀) value of KRG-TS in thrombin-stimulated human platelet aggregation. Measurement of platelet aggregation was carried out as described in the “Materials and methods” section. The rate of inhibition by KRG-TS was recorded as the percentage of thrombin-induced aggregation rate. The IC₅₀ value of KRG-TS was calculated according to the four-parameter log-fit method. Data are expressed as the mean ± standard deviation (n = 4). *p < 0.05 versus the thrombin-induced human platelet aggregation.
20; Promega, Madison, WI, USA) using an ATP assay kit. Serotonin release was measured with a Synergy HT Multi-Mode Microplate Reader (BioTek Instruments, Winooski, VT, USA) using a serotonin ELISA kit.

2.6. Western blot analysis for evaluation of PKA catalytic subunit and IP3R phosphorylation

Washed platelets (10^9/mL) were preincubated with or without KRG-TS in the presence of 2mM CaCl	extsubscript{2} for 3 min and then stimulated with thrombin (0.05 U/mL) for 5 min at 37°C. The reactions were terminated by adding an equal volume (250 µL) of lysis buffer (20mM Tris—HCl, 150mM NaCl, 1mM Na2EDTA, 1mM ethylene glycol tetraacetic acid, 1% Triton X-100, 2.5mM sodium pyrophosphate, 1mM serine/threonine phosphatase inhibitor β-glycerophosphate, 1mM ATPase, alkaline and acid phosphatase, protein phosphotyrosine phosphatase inhibitor Na3VO4, 1 µg/mL serine and cysteine protease inhibitor leupeptin, and 1mM serine protease and acetylcholinesterase inhibitor phenylmethanesulfonyl fluoride; pH 7.5). Platelet lysates containing the same protein (15 µg/mL) were used for protein transfer from the gel. The dilutions for anti-phospho-IP3R (Ser1756), anti-phospho-PKAc (Thr197), and antirabbit IgG (20mM Tris—HCl, pH 8.8, 0.05% SDS, 5% BSA, 0.1% Tween-20) were 1:1,000, 1:1,000, and 1:10,000, respectively. The membranes were visualized using ECL. Blots were analyzed using the Quantity One version 4.5 software (BioRad, Hercules, CA, USA).

2.7. Statistical analyses

The experimental results were expressed as the mean ± standard deviation accompanied by the number of observations. Data were assessed by analysis of variance. If this analysis indicated significant differences among the group means, then each group was compared by the Newman–Keuls method. Statistical analysis was performed using SPSS 21.0.0 (SPSS Inc., Chicago, IL, USA). A p value < 0.05 was taken to be significant.

3. Results

3.1. Effects of KRG-TS on thrombin-induced human platelet aggregation

The concentration of thrombin-induced maximal human platelet aggregation was approximately 0.05 U/mL (Fig. 1A). Therefore, 0.05 U/mL thrombin was used as the human platelet agonist in this study. The light transmission in response to various concentrations of KRG-TS in intact platelets was 1.3 ± 0.6% (at 25 µg/mL of KRG-TS), 1.3 ± 0.6% (at 50 µg/mL of KRG-TS), 1.3 ± 0.6% (at 100 µg/mL of KRG-TS), and 1.3 ± 0.6% (at 150 µg/mL of KRG-TS), which was not significantly different from that observed in resting platelets [1.0 ± 0.0%; Fig. 1B(a–c)]. This result indicated that KRG-TS alone did not have an effect on platelet aggregation. When washed human platelets (10^9/mL) were activated with thrombin, the aggregation rate was increased up to 87.8 ± 5.7%. However, various concentrations of KRG-TS (25–150 µg/mL) significantly reduced thrombin-stimulated platelet aggregation in a dose-dependent manner (Fig. 1C), and its half-maximal inhibitory concentration (IC50) was 45 µg/mL (Fig. 1D). This IC50 is low compared with that (81 µg/mL) by rat platelets [18]. In addition,
Fig. 3. Effects of total saponin from Korean Red Ginseng (KRG-TS) on thrombin-induced \([\text{Ca}^{2+}]_i\) mobilization. (A) Inhibitory effects of KRG-TS on thrombin-induced \([\text{Ca}^{2+}]_i\) mobilization. (B) Effects of KRG-TS on \([\text{Ca}^{2+}]_i\) mobilization in the presence of cyclic adenosine monophosphate-dependent protein kinase inhibitor (Rp-8-Br-cAMPS). (C) Effects of KRG-TS on \([\text{Ca}^{2+}]_i\) mobilization in the presence of cyclic guanosine monophosphate-dependent protein kinase inhibitor (Rp-8-Br-cGMPS). \([\text{Ca}^{2+}]_i\) was determined as described in the “Materials and methods” section. Data are expressed as the mean ± standard deviation (n = 4). *p < 0.05 versus the thrombin-stimulated human platelets. **p < 0.05 versus the thrombin-stimulated human platelets in the presence of KRG-TS (150 μg/mL). ***p < 0.05 versus the thrombin-stimulated human platelets in the presence of KRG-TS (150 μg/mL).
150 μg/mL of KRG-TS inhibited up to 95.9% of thrombin-induced human platelet aggregation (87.8 ± 5.7%).

3.2. Effects of KRG-TS on thrombin-induced human platelet aggregation in the presence of PKA or PKG inhibitor

Because [Ca$^{2+}$]$_i$ is essential for platelet aggregation, we investigated the effect of KRG-TS on thrombin-induced platelet aggregation in the presence of PKA or PKG inhibitor, both of which are intracellular Ca$^{2+}$-antagonistic compounds. As shown in Fig. 2A, thrombin increased light transmission [Fig. 2A(a)], whereas KRG-TS decreased thrombin-induced light transmission [Fig. 2A(d)]. The PKA inhibitor Rp-8-Br-cAMPS [Figs. 2A(b) and 2B] and the PKG inhibitor Rp-8-Br-cGMPS [Figs. 2A(c) and 2B] increased KRG-TS-attenuated light transmission in thrombin-activated platelets. The inhibitory degree [Figs. 2A(b) and 2B] achieved by the PKA inhibitor was more stronger than that achieved by the PKG inhibitor [Figs. 2A(c) and 2B]. These results suggest that the inhibition of thrombin-induced human platelet aggregation by KRG-TS is greatly dependent on cAMP-dependent Ca$^{2+}$-antagonistic condition than cGMP-dependent Ca$^{2+}$-antagonistic condition.

3.3. Effects of KRG-TS on [Ca$^{2+}$]$_i$ mobilization

We investigated the effect of KRG-TS on Ca$^{2+}$-antagonistic activity. As shown in Fig. 3A, thrombin increased the [Ca$^{2+}$]$_i$ level from 101.2 ± 0.5nM (basal level) to 590.6 ± 18.3nM (Fig. 3A, inset table). However, this was significantly decreased by various concentrations (25–150 μg/mL) of KRG-TS in a dose-dependent manner (Fig. 3A). If the inhibition of [Ca$^{2+}$]$_i$ mobilization by KRG-TS results from IP$_3$R phosphorylation through the cAMP/PKA or cGMP/PKG pathway, then the KRG-TS-reduced [Ca$^{2+}$]$_i$ level would be increased by the PKA or PKG inhibitor. Accordingly, we investigated the effects of PKA inhibitor (Rp-8-Br-cAMPS) and PKG inhibitor (Rp-8-Br-cGMPS) on KRG-TS-reduced [Ca$^{2+}$]$_i$ mobilization. As shown in Fig. 3B, the PKA inhibitor Rp-8-Br-cAMPS (50–250μM) dose dependently increased the [Ca$^{2+}$]$_i$ level compared with that (110.9 ± 1.9 nM) by KRG-TS (150 μg/mL) in the thrombin-induced platelet aggregation. By contrast, the PKG inhibitor Rp-8-Br-

| Table 1 | Effects of Rp-8-Br-cAMPS and Rp-8-Br-cGMPS on [Ca$^{2+}$]$_i$ mobilization |
|---------|------------------------------------------------------------------|
| KRG-TS (150 μg/mL) + thrombin (0.05 U/mL) | 110.9 ± 1.9 | - |
| KRG-TS (150 μg/mL) + Rp-8-Br-cAMPS (250μM) + thrombin (0.05 U/mL) | 238.6 ± 5.9 | 155.1$^1$ |
| KRG-TS (150 μg/mL) + Rp-8-Br-cGMPS (250μM) + thrombin (0.05 U/mL) | 143.6 ± 2.8 | 29.4$^2$ |

Data are from Figs. 3B and 3C

KRG-TS, total saponin from Korean Red Ginseng

1) Increase (%) = \[ \frac{[\text{KRG-TS} + \text{thrombin} + \text{Rp-8-Br-cAMPS}] - [\text{KRG-TS} + \text{thrombin}]}{[\text{KRG-TS} + \text{thrombin}]} \times 100 \]

2) Increase (%) = \[ \frac{[\text{KRG-TS} + \text{thrombin} + \text{Rp-8-Br-cGMPS}] - [\text{KRG-TS} + \text{thrombin}]}{[\text{KRG-TS} + \text{thrombin}]} \times 100 \]

Fig. 4. Effect of total saponin from Korean Red Ginseng (KRG-TS) on cyclic adenosine monophosphate-dependent protein kinase catalytic subunit (PKAc) phosphorylation. Lane 1, intact platelets (base); Lane 2, thrombin (0.05 U/mL); Lane 3, thrombin (0.05 μg/mL) + KRG-TS (50 μg/mL); Lane 4, thrombin (0.05 μg/mL) + KRG-TS (100 μg/mL); Lane 5, thrombin (0.05 U/mL) + KRG-TS (150 μg/mL); Lane 6, thrombin (0.05 U/mL) + KRG-TS (150 μg/mL) + Rp-8-Br-cAMPS (250μM); and Lane 7, thrombin (0.05 U/mL) + 8-(4-chlorophenylthio)-cyclic adenosine monophosphate (pCPT-cAMP; 1mM). Western blotting was performed as described in the “Materials and methods” section. Data are expressed as the mean ± standard deviation (n = 4). *p < 0.05 versus the thrombin-stimulated human platelets. **p < 0.05 versus the thrombin-stimulated human platelets in the presence of KRG-TS (150 μg/mL).
3.4. Effects of KRG-TS on PKAc (Thr197) phosphorylation

It is well-known that the phosphorylation of PKAc (Thr197) is necessary to produce biological functions through the cAMP/PKA pathway [23]. As shown in Fig. 4, KRG-TS dose dependently phosphorylated Thr197 in PKAc (42 kDa), and abruptly increased the ratio of phosphorylated PKAc (Thr197) to β-actin in thrombin-induced platelet aggregation (Fig. 4, lanes 4 and 5). The PKA inhibitor Rp-8-Br-cAMPS strongly decreased KRG-TS-elevated phosphorylation of PKAc (Thr197) (Fig. 4, lane 6), meaning that the phosphorylation of PKAc (Thr197) by KRG-TS depends on the cAMP/PKA pathway. This is also supported by the fact that the PKA activator 8-(4-chlorophenylthio)cAMP (pCPT-cAMP) increased the phosphorylation of PKAc (Thr197) (Fig. 4, lane 7).

3.5. Effects of KRG-TS on IP3RI (Ser1756) phosphorylation in the presence of PKA and PDK inhibitors

We then investigated the IP3RI phosphorylation-associated PKAc (Thr197) phosphorylation. The phosphorylation of IP3RI (Ser1756) and the ratio of phosphorylated IP3RI (p-IP3RI; Ser1756) to β-actin were increased in the presence of the PKA activator pCPT-cAMP (Fig. 5, lane 7) in thrombin-induced human platelet aggregation, indicating that cAMP/PKA is involved in the phosphorylation of IP3RI (Ser1756). As shown in Fig. 5 (lanes 3 and 4), the phosphorylation of IP3RI (Ser1756) and the ratio of p-IP3RI (Ser1756) to β-actin were dose dependently increased in the presence of both thrombin and KRG-TS. To investigate whether cAMP/PKA (Thr197) phosphorylation by KRG-TS (Fig. 4, lane 5) is involved in IP3RI phosphorylation (Fig. 5, lane 4), we used the PKA inhibitor Rp-8-Br-cAMPS (Fig. 4, lane 6) that inhibited KRG-TS-induced PKAc (Thr197) phosphorylation. As shown in Fig. 5 (lane 5), the PKA inhibitor Rp-8-Br-cAMPS strongly decreased KRG-TS-elevated phosphorylation of IP3RI (Ser1756) (Fig. 5, lane 4) that inhibited KRG-TS-induced PKAc (Thr197) phosphorylation (Fig. 4, lane 6).

Table 2

| Conditions                                      | Ratio of p-IP3RI to β-actin | Δ (%)       |
|------------------------------------------------|-----------------------------|------------|
| Thrombin (0.05 U/mL)                           | 2.7 ± 0.1                   |            |
| KRG-TS (150 µg/mL) + thrombin (0.05 U/mL)      | 267.6 ± 7.3                 | +9811.11   |
| KRG-TS (150 µg/mL) + Rp-8-Br-cAMPS (250µM)     | 148.9 ± 2.1                 | -44.3      |
| KRG-TS (150 µg/mL) + thrombin (0.05 U/mL) + Rp-8-Br-cAMPS (250µM) | 196.2 ± 8.5 | -26.6      |

Data are from Fig. 5

IP3RI, inositol 1,4,5-trisphosphate receptor; KRG-TS, total saponin from Korean Red Ginseng

Note:

1. Δ (%) = [(KRG-TS + thrombin) - (KRG-TS + thrombin) × 100
2. Δ (%) = [(KRG-TS + thrombin + Rp-8-Br-cAMPS) - (KRG-TS + thrombin)]/(KRG-TS + thrombin) × 100
3. Δ (%) = [(KRG-TS + thrombin + Rp-8-Br-cAMPS) - (KRG-TS + thrombin)]/(KRG-TS + thrombin) × 100

Fig. 5. Effect of total saponin from Korean Red Ginseng (KRG-TS) on inositol 1,4,5-trisphosphate receptor type I (IP3RI) (Ser1756) phosphorylation. Lane 1, intact platelets (base); Lane 2, thrombin (0.05 U/mL); Lane 3, thrombin (0.05 U/mL) + KRG-TS (100 µg/mL); Lane 4, thrombin (0.05 U/mL) + KRG-TS (150 µg/mL); Lane 5, thrombin (0.05 U/mL) + KRG-TS (150 µg/mL) + Rp-8-Br-cAMPS (250µM); Lane 6, thrombin (0.05 U/mL) + KRG-TS (150 µg/mL) + Rp-8-Br-cGMP (250µM); Lane 7, thrombin (0.05 U/mL) + 8-(4-chlorophenylthio)cyclic adenosine monophosphate (pCPT-cAMP; 1mM); and Lane 8, thrombin (0.05 U/mL) + 8-Br-cGMP (1mM). Western blotting was performed as described in the "Materials and methods" section. Data are expressed as the mean ± standard deviation (n = 4). *p < 0.05 versus the thrombin-stimulated platelets, **p < 0.05 versus the thrombin-stimulated human platelets in the presence of KRG-TS (150 µg/mL).
Fig. 6. Effects of total saponin from Korean Red Ginseng (KRG-TS) on adenosine triphosphate (ATP) and serotonin release. (A) Effects of KRG-TS on ATP release in thrombin-activated platelets. (B) Effects of KRG-TS on ATP release in the presence of cyclic adenosine monophosphate-dependent protein kinase (PKA) or cyclic guanosine monophosphate-dependent protein kinase (PKG) inhibitor. (C) Effects of KRG-TS on serotonin release. (D) Effects of KRG-TS on serotonin release in the presence of PKA or PKG inhibitor. Data are expressed as mean ± standard deviation (n = 4). *p < 0.05 versus the thrombin-stimulated human platelets. **p < 0.05 versus the thrombin-stimulated human platelets in the presence of KRG-TS (150 μg/mL).
inhibitor Rp-8-Br-cAMPS potently decreased p-IP3R (Ser1756) and the ratio of p-IP3RI (Ser1756) to β-actin achieved by both thrombin and KRG-TS. These results indicate that the increase of p-IP3R (Ser1756) by KRG-TS is dependent on cAMP/PKA (Th197). The PKG inhibitor Rp-8-Br-cGMPMS also decreased KRG-TS-induced p-IP3RI (Ser1756; Fig. 5, lane 6). However, its inhibitory degree (22.6%) was lower compared with that of the PKA inhibitor Rp-8-Br-cAMPS (44.3%; Table 2), indicating that the increase of p-IP3R (Ser1756) by KRG-TS is effected through the cAMP/PKA pathway.

3.6. Effects of KRG-TS on ATP and serotonin release

Intracellular [Ca2+]i mobilization is known to be involved in the release of ATP and serotonin from a dense body of platelets [24]. Because KRG-TS inhibited thrombin-elevated [Ca2+]i mobilization (Fig. 3A), we investigated whether KRG-TS is involved in the inhibition of ATP and serotonin release. As shown in Fig. 6, KRG-TS dose dependently inhibited thrombin-induced ATP (Fig. 6A) and serotonin release (Fig. 6C). Because the inhibition of [Ca2+]i mobilization by KRG-TS was dependent on cAMP/PKA and cGMP/PKG pathways, we investigated whether the inhibition of ATP and serotonin release by KRG-TS resulted from cAMP/PKA and cGMP/PKG pathways. The PKA inhibitor Rp-8-Br-cAMPS (Fig. 6B) and the PKG inhibitor Rp-8-Br-cGMPMS (Fig. 6D) increased KRG-TS-decreased ATP and serotonin release.

These results indicate that the inhibition of ATP and serotonin release by KRG-TS (Figs. 6A and 6C) is dependent on the cAMP/PKA and cGMP/PKG pathways. The results are supported by the fact that the PKA activator pCPT-cAMP (Fig. 6B) and the PKG activator 8-Br-cGMP (Fig. 6D) inhibit thrombin-induced ATP and serotonin release.

3.7. Effects of ginsenosides in KRG-TS on thrombin-induced platelet aggregation

In a previous report [18], five ginsenosides (G-Rh1, G-Rb2, G-Rc, G-Rd, and G-Rg3) were reported as 20(S)-PPDS and three ginsenosides (G-Re, G-Rg1, and G-Rg2) as 20(S)-PPTS. Besides these ginsenosides, it is known that G-Ra1, G-Rb3, and G-Rh2 as PPDS and G-Rf and G-Rh1 as PPTS are also present in P. ginseng [25]. Therefore, to investigate which ginsenoside of KRG-TS was involved in the inhibition of thrombin-induced human platelet aggregation, we investigated the effect of ginsenosides in KRG-TS and other ginsenosides on thrombin-induced human platelet aggregation. In this study, G-Ra1, G-Rb1, G-Rb2, G-Rb3, G-Rc, G-Rd, and G-Rh2(20R) of PPDS did not inhibit thrombin-induced human platelet aggregation, but only G-Rg3 (20R, 20S) dose dependently inhibited thrombin-induced human platelet aggregation (Table 3). In addition, none of the PPTSs [G-Re, G-Rf, G-Rg1, G-Rg2 (20R), and G-Rh1 (20S)] inhibited thrombin-induced human platelet aggregation (Table 4).

4. Discussion

Although KRG-TS elevated cAMP only in thrombin-induced human platelets [17], to confirm whether the cAMP/PKA or cGMP/PKG pathway contributed to the inhibition of platelet aggregation by KRG-TS, we investigated the effect of PKA inhibitor and PKG inhibitor on thrombin-induced human platelet aggregation in the presence of KRG-TS. The results showed that the PKA inhibitor Rp-8-Br-cAMPS and the PKG inhibitor Rp-8-Br-cGMPMS increased KRG-TS-decreased light transmission in thrombin-induced human platelet aggregation. However, the elevation of light transmission by the PKA inhibitor was stronger than that by the PKG inhibitor in KRG-TS-inhibited thrombin-induced human platelet aggregation. These results show that the cAMP/PKA pathway mainly contributed to the inhibition of thrombin-induced platelet aggregation and [Ca2+]i mobilization by KRG-TS. Several aggregation-inducing molecules ([Ca2+]i, TXA2, etc.) are commonly generated by agonists such as thrombin, collagen, and adenosine diphosphate (ADP). The IP3 mobilizes [Ca2+]i, and subsequently activates Ca2+-dependent PLC or phospholipase-A2 to separate the IP3 and TXA2 production by COX-1/TXAS. These results show that the cAMP/PKA pathway mainly contributed to the inhibition of thrombin-induced platelet aggregation and [Ca2+]i mobilization by KRG-TS.

### Table 3

| Treatment (µM) | Aggregation (%) | Treatment (µM) | Aggregation (%) |
|---------------|-----------------|----------------|----------------|
| Thrombin (0.05 U/mL) | 86.7 ± 1.5 | Ginsenoside Rg1 | 86.7 ± 1.5 |
| 50            | 83.3 ± 1.2     | 50             | 85.0 ± 3.0    |
| 10            | 83.0 ± 1.7     | 100            | 84.0 ± 1.7    |
| 200           | 83.0 ± 1.0     | 200            | 86.3 ± 1.5    |
| 300           | 86.7 ± 1.5     | 300            | 84.3 ± 4.0    |
| Ginsenoside Rb1 | 86.7 ± 1.5 | Ginsenoside Rg3 (20R) | 86.7 ± 1.5 |
| 50            | 83.0 ± 1.7     | 50             | 86.7 ± 1.5    |
| 100           | 84.3 ± 0.6     | 100            | 86.0 ± 2.0    |
| 200           | 85.3 ± 3.1     | 200            | 75.7 ± 3.2    |
| 300           | 83.0 ± 3.5     | 300            | 62.0 ± 2.0    |
| Ginsenoside Rb2 | 86.7 ± 1.5 | Ginsenoside Rg3 (20S) | 86.7 ± 1.5 |
| 50            | 82.3 ± 3.5     | 50             | 83.3 ± 1.2    |
| 100           | 85.7 ± 1.2     | 100            | 84.7 ± 0.6    |
| 200           | 83.7 ± 1.5     | 200            | 85.3 ± 3.1    |
| 300           | 84.0 ± 1.6     | 300            | 81.0 ± 1.7    |
| Ginsenoside Rg3 | 86.7 ± 2.2 | Ginsenoside Rg2 (20R) | 86.7 ± 2.2 |
| 50            | 82.4 ± 3.2     | 50             | 83.3 ± 1.2    |
| 100           | 84.7 ± 0.6     | 100            | 84.5 ± 0.6    |
| 200           | 86.3 ± 2.1     | 200            | 85.3 ± 2.1    |
| 300           | 84.0 ± 2.6     | 300            | 73.7 ± 1.5**  |

Results are expressed as percentage of aggregation induced by thrombin. The data are expressed as the mean ± standard deviation (n = 4)

*p < 0.05, **p < 0.01 versus the thrombin-stimulated human platelets

### Table 4

| Treatment (µM) | Aggregation (%) | Treatment (µM) | Aggregation (%) |
|---------------|-----------------|----------------|----------------|
| Thrombin (0.05 U/mL) | 86.7 ± 1.5 | Ginsenoside Rg1 | 86.7 ± 1.5 |
| 50            | 83.2 ± 1.2     | 50             | 84.0 ± 2.6    |
| 100           | 82.3 ± 1.5     | 100            | 87.0 ± 1.0    |
| 200           | 85.3 ± 2.5     | 200            | 85.3 ± 2.9    |
| 300           | 84.7 ± 0.6     | 300            | 86.0 ± 2.6    |
| Ginsenoside Rf | 86.7 ± 1.5 | Ginsenoside Rhl (20S) | 86.7 ± 1.5 |
| 50            | 82.7 ± 2.1     | 50             | 84.3 ± 1.5    |
| 100           | 86.7 ± 1.5     | 100            | 83.3 ± 2.1    |
| 200           | 84.7 ± 0.6     | 200            | 82.7 ± 1.2    |
| 300           | 83.0 ± 1.0     | 300            | 85.3 ± 2.5    |
| Ginsenoside Rg1 | 86.4 ± 3.2 | Ginsenoside Rhl (20S) | 86.4 ± 3.2 |
| 50            | 84.3 ± 2.1     | 50             | 84.3 ± 1.5    |
| 100           | 83.0 ± 1.7     | 100            | 84.3 ± 1.7    |
| 200           | 84.7 ± 0.4     | 200            | 85.0 ± 1.0    |
| 300           | 85.0 ± 1.0     | 300            | 85.3 ± 2.5    |

Results are expressed as percentage of aggregation induced by thrombin. The data are expressed as the mean ± standard deviation (n = 4)
production by attenuating COX-1 and TXAS activities. Although KRG-TS inhibited thrombin-induced [Ca\(^{2+}\)]\(_i\) mobilization, its inhibitory mechanism is unknown. The Ca\(^{2+}\)-antagonistic reaction by cAMP and cGMP is mediated by both PKA/IP\(_\text{3}\)RI and PKG/IP\(_\text{3}\)RI phosphorylation pathways. Because KRG-TS elevated the level of camp [18], if KRG-TS stimulates IP\(_\text{3}\)RI (Ser\(^{1756}\)) phosphorylation in thrombin-activated human platelets, it is clear evidence that KRG-TS inhibits [Ca\(^{2+}\)]\(_i\) mobilization through the cAMP/PIK/PI\(_\text{3}\)RI (Ser\(^{1756}\)) phosphorylation pathway. In this report, we confirmed that KRG-TS inhibited [Ca\(^{2+}\)]\(_i\) mobilization through cAMP/PIK/PI\(_\text{3}\)RI (Ser\(^{1756}\)) phosphorylation by cAMP/PIK/PI\(_\text{3}\)RI, which is supported by the fact that the cAMP inhibitor Rp-8-Br-cAMPS inhibited KRG-TS-induced thrombin-activated human platelet aggregation, otherwise the cAMP inhibitor Rp-8-Br-cAMPS would not increase KRG-TS-decreased [Ca\(^{2+}\)]\(_i\) mobilization in thrombin-induced human platelet aggregation. It is known that IP\(_3\) induces serotonin release from platelet-dense bodies, meaning that IP\(_3\) is involved in serotonin release by elevating [Ca\(^{2+}\)]\(_i\), through IP\(_3\)RI [29]. This reflects the fact that KRG-TS may be involved in the inhibition of serotonin release by phosphorylating IP\(_3\)RI (Ser\(^{1756}\)).

A lot of agonists such as collagen, thrombin, and ADP mobilize [Ca\(^{2+}\)]\(_i\) to phosphatidylinositol 4,5-bisphosphate [Pi]-dependent myosin light chain (20 kDa), which plays a role in secretion of granules such as serotonin and ATP [6,7], and platelet aggregation. It is thought that the inhibition of ATP and serotonin secretion by KRG-TS results from the elevation of Ca\(^{2+}\)-antagonistic molecule cAMP and subsequent inhibition of [Ca\(^{2+}\)]\(_i\) mobilization, which is also supported by the fact that KRG-TS stimulated the phosphorylation of both PKA (Thr\(^{197}\)) and IP\(_3\)RI (Ser\(^{1756}\)). Platelet aggregation is generated at the site of vascular wall injury, and is involved in the formation of thrombus. During the formation of thrombus, platelets release cell growth proteins [e.g., platelet-derived growth factor (PDGF)] and vascular endothelial growth factor (VEGF) in x-granules [30,31]. It is well-established that PDGF and VEGF induce the proliferation of fibroblast, vascular smooth cells, and epithelial cells, and subsequently enhance the rate of atherosclerosis lesion progression [32–36]. The progression of atherosclerosis is strongly induced by inflammatory cells such as monocytes/macrophages and neutrophils [37]. Although KRG-TS shows antiplatelet effects, if KRG-TS does not inhibit inflammation by leukocytes, progression of atherosclerosis lesion occurs at the site of vascular wall injury, which raises questions about the antiplatelet effects of KRG-TS. Byeon et al [38] reported that saponin fraction inhibits lipopolysaccharide (LPS)-induced inflammation, and it is well-known that ginsenosides exhibit anti-inflammatory effects by inhibiting the production of various proinflammatory mediators such as prostaglandin E\(_2\) and NO [39]. Recently, it was reported that saponin fractions of KRG downregulate LPS-induced proinflammatory mediators (i.e., NO and interleukin-1β) [40]. Considering these three previous reports [38–40], it is thought that KRG-TS may exhibit antiinflammatory and antithrombotic effects without causing inflammation and progression of atherosclerotic lesion at the site of vascular wall injury. Therefore, KRG-TS is highlighted as a “nontoxic antiplatelet compound,” and could be clinically applied to the prevention of platelet-mediated thrombosis. This result is supported by a previous study suggesting the protective effects of KRG on carotid artery thrombosis in vivo in rats [41]. In addition, both ginseng and ginsenosides are very useful for prevention of cardiovascular disease [42].

With regard to the antiplatelet effects of ginsenosides in KRG-TS, only G-Rg3 (20R, 20S) inhibited thrombin-induced platelet aggregation. This is in accordance with the reports that G-Rg3 (20R, 20S) inhibited arachidonic acid- or U46619-induced platelet aggregation [43], and its analog (G-Rp1, dihydroxy G-Rg3) inhibited collagen- or thrombin-induced platelet aggregation [19,20]. Other reports also suggested that G-Rg1 [molecular weight (MW) = 800.94] and G-Rg2 (MW = 781.01) inhibit various agonists (i.e., thrombin, collagen, ADP)-induced platelet aggregation [44–46], but the inhibitory concentrations were 1 mg/mL (1.2mM) to 4 mg/mL (5mM) for G-Rg1 [44,45] and 1 mg/mL (1.3mM) for G-Rg2 [45,46]. These inhibitory concentrations (1.2–5mM) of G-Rg1 or G-Rg2 (1.3mM) [44–46] are very high compared with those of G-Rg3 and its analogues (G-Rp1, dihydroxy G-Rg3), which exhibited antiplatelet effect at concentrations in the range of micromoles [19,20,43]. Therefore, it is thought that the antiplatelet effects exhibited by G-Rg1 and G-Rg2 should be re-evaluated. Because only G-Rg3 in KRG-TS inhibited thrombin-induced human platelet aggregation, it is thought that G-Rg3 in KRG-TS might have contributed to the inhibition of platelet aggregation and [Ca\(^{2+}\)]\(_i\) mobilization, which also supports the report that G-Rg3 elevated Ca\(^{2+}\)-antagonistic cAMP levels [20].

Thrombosis mainly results from the irreversible aggregation, which is closely related to the serotonin released from platelets activated by agonists (i.e., collagen and thrombin) [47–49]. In addition, the released serotonin is involved in causing migraine [50–52].

In conclusion, the most important result of this study is that KRG-TS significantly phosphorylates IP\(_3\)RI (Ser\(^{1756}\)) to inhibit thrombin-induced [Ca\(^{2+}\)]\(_i\) mobilization, which contributed to attenuating the release of ATP and serotonin. Therefore, our results suggest that KRG-TS may be a physiologically effective negative regulator in platelet aggregation, a cause of thrombosis, atherosclerosis, and myocardial infarction. Because KRG-TS also inhibits serotonin release, it should also be evaluated as an antimigraine substance.

Conflicts of interest
The authors declare no conflict of interest.

Acknowledgments
This study was supported by a grant (Grant No. NRF-2011-0012143 to H.-J.P.) from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology, Korea.

References
[1] Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev 1990;70:1177–209.
[2] Berridge MJ, Irvine RF. Insoluble trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984;312:315–21.
[3] Cattaneo M. The P2 receptors and congenital platelet function defects. Semin Thromb Hemost 2005;31:168–73.
[4] Guidetti G, Lova P, Bernardi R, Campus F, Baldanzi G, Graziani A, Balduni C, Torri M. The Gi-coupled 72Y12 receptor regulates diacylglycerol-mediated signaling in human platelets. J Biol Chem 2008;283:28795–805.
[5] Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol 2009;103:4A–10A.
[6] Hashikawa M, Tanaka T, Hidaka H. Ca\(^{2+}\)-calmodulin-dependent phosphorylation and platelet secretion. Nature 1980;287:863–5.
[7] Kaibuchi K, Sano K, Hoshijima M, Takai Y, Nishizuka Y. Phosphatidylinositol turnover in platelet activation; calcium mobilization and protein phosphorylation. Cell Calcium 1982;3:323–35.
[8] Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001;62:1153–61.
[9] Cavallini L, Coassin M, Borean A, Alexandre A. Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem 1996;271:5545–51.
[10] Quinton TM, Dean WL. Cyclic AMP-dependent phosphorylation of the inositol-1,4,5-trisphosphate receptor inhibits Ca\(^{2+}\) release from platelet membranes. Biochem Biophys Res Commun 1992;194:893–9.
Moriyama T, Takamura H, Narita H, Tanaka K, Matsuura T, Kito M. Elevation of
Choi KT. Botanical characteristics, pharmacological effects and medicinal
Lee DH, Cho HJ, Kang HY, Rhee MH, Park HJ. Total saponin from Korean Red
Hwang SY, Son DJ, Kim IW, Kim DM, Sohn SH, Lee JJ, Kim SK. Korean Red
Jung YH, Park KY, Jeon JH, Kwak YS, Song YB, Do JH, Kim OC, Lee SD. Identification of
Antioxidant components in Korean Red Ginseng. J Ginseng Res 2010;34:355–62.
Jung TH, Park KY, Jeon JH, Kwak YS, Song YB, Wee JJ, Rhee MH, Kim TW. Red
Ginseng saponin fraction A isolated from Korean Red Ginseng by ultrafiltration
through suppression of diacylglycerol liberation in high-cholesterol-diet-fed rabbits. Phytother Res 2008;6:778–83.
Lee DH, Cho HJ, Kang HY, Rhee MH, Park HJ. Total saponin from Korean Red
Ginseng inhibits thromboxane A2 production associated microsomal enzyme
activity in platelets. J Ginseng Res 2012;36:40–6.
Lee DH, Cho HJ, Kim HH, Rhee MH, Ryu JH, Park HJ. Inhibitory effects of total
saponin from Korean Red Ginseng via vasodilator-stimulated phosphoprotein-
Ser(157) phosphorylation on thrombin-induced platelet aggregation. J Ginseng Res 2013;37:176–86.
Endale M, Lee WM, Kamruzzaman SM, Kim SD, Park JY, Park MH, Park TY, Park HJ, Cho JY, Rhee MH. Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation. Br J Pharmacol 2012;167:109–27.
Lee WM, Kim SD, Park MH, Cho JY, Park HJ, Seo GS, Rhee MH. Inhibitory mechanisms of dihydroginsenoside Rg3 in platelet aggregation: critical roles of ERK2 and cAMP. J Pharm Pharmacol 2008;60:1531–6.
Lee SR, Park JH, Kim ND, Choi KJ. Inhibitory effects of ginsenoside Rg3 on platelet aggregation and its mechanism of action. J Ginseng Res 1997;21:132–40.
Schaeffer J, Blaustein MP. Platelet free calcium concentrations measured with fura-2 are influenced by the transmembrane sodium gradient. Cell Calcium 1989;10:101–13.
Jin HK, Wu TX, Jiang YJ, Zou JW, Zhuang SL, Mao X, Yu QS. Role of phospholipase Thr-197 in the catalytic subunit of cAMP-dependent protein ki-
nase. J Mol Struct 2007;805:9–15.
Charo IF, Feinman RD, Detwiler TC. Inhibition of platelet secretion by an
800,000 D molecule from human blood platelets. Nature 1981;291:787–9.
Endale M, Lee WM, Kamruzzaman SM, Kim SD, Park JY, Park MH, Park TY, Park HJ, Cho JY, Rhee MH. Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation. Br J Pharmacol 2012;167:109–27.
Lee WM, Kim SD, Park MH, Cho JY, Park HJ, Seo GS, Rhee MH. Inhibitory mechanisms of dihydroginsenoside Rg3 in platelet aggregation: critical roles of ERK2 and cAMP. J Pharm Pharmacol 2008;60:1531–6.
Lee SR, Park JH, Kim ND, Choi KJ. Inhibitory effects of ginsenoside Rg3 on platelet aggregation and its mechanism of action. J Ginseng Res 1997;21:132–40.
Schaeffer J, Blaustein MP. Platelet free calcium concentrations measured with fura-2 are influenced by the transmembrane sodium gradient. Cell Calcium 1989;10:101–13.
Jin HK, Wu TX, Jiang YJ, Zou JW, Zhuang SL, Mao X, Yu QS. Role of phospholipase Thr-197 in the catalytic subunit of cAMP-dependent protein kinase. J Mol Struct 2007;805:9–15.
Charo IF, Feinman RD, Detwiler TC. Inhibition of platelet secretion by an antagonist of intracellular calcium. Biochem Bioph Res Comm 1976;72:1462–7.
Choi KT. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin 2008;29:1109–18.
Moriyama T, Takamura H, Narita H, Tanaka K, Matsusura T, Kito M. Elevation of cytosolic free Ca2+ is directly evoked by thromboxane A2 in human platelets during activation with collagen. J Biochem 1988;103:901–2.
Charo IF, Feinman RD, Detwiler TC. Interrelations of platelet aggregation and secretion. J Clin Invest 1977;60:866–73.
Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978;30:293–331.
Authi KS, Evenden BJ, Crawford N. Metabolic and functional consequences of introducing inositol 1,4,5-trisphosphate into saponin-permeabilized human platelets. Biochem J 1986;233:707–18.
Castro-Malaspina H, Rabellino EM, Yen A, Nachman RL, Moore MA. Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood 1981;57:781–7.
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zaggard D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression, and growth in tu-
mors mediated by angiopoietins and VEGF. Science 1999;284:1994–8.
Nagai R, Suzuki T, Aizawa K, Shindo T, Manabe I. Significance of the tran-
scription factor KLF5 in cardiovascular remodeling. J Thorm Haemost 2005;3:1569–76.
Schwartz SM, Reidy MA. Common mechanisms of proliferation of smooth
muscle in atherosclerosis and hypertension. Hum Pathol 1987;18:240–7.
Packham MA, Mustard JF. The role of platelets in the development and complications of atherosclerosis. Semin Hematol 1986;23:8–26.
Schwartz SM, Ross R. Cellular proliferation in atherosclerosis and hyperten-
sion. Prog Cardiovasc Dis 1984;26:355–72.
Seppa H, Grotendorst G, Seppa S, Schillfmann E, Martin GR. Platelet-derived growth factor in chemotactic for fibroblasts. J Cell Biol 1982;92:584–8.
Phillips DR, Conley PR, Sinha U, Andre P. Therapeutic approaches in arterial thrombosis. J Thorm Haemost 2005;3:1577–89.
Byeon SE, Choi WS, Hong EK, Lee J, Rhee MH, Park HJ, Cho YJ. Inhibitory effect of saponin fraction from Codonopsis lanceolata on immune cell-mediated infl-
ammatory responses. Arch Pharm Res 2009;32:813–22.
Park JS, Cho JY. Anti-inflammatory effects of ginsenosides from Panax ginseng and their structural analogs. Aflr J Biotechnol 2009;8:3682–90.
Lee YJ, Han JY, Lee CG, Heo K, Park SI, Park YS, Kim JS, Yang KM, Lee KJ, Kim TH, et al. Korean Red Ginseng saponin fraction modulates radiation effects on lipopolysaccharide-stimulated nitric oxide production in RAW264.7 macro-
phage cells. J Ginseng Res 2014;38:208–14.
Jin YR, Yu JJ, Lee JH, You SH, Chung JH, Noh JY, Im JH, Han KH, Kim TJ, Shin KS, et al. Anti-thrombotic and antiplatelet activities of Korean Red Ginseng extract. Basic Clin Pharmacol Toxicol 2007;100:170–5.
Lee CH, Kim JH. A review on the medicinal potentials of ginseng and ginsenos-
ides on cardiovascular diseases. J Ginseng Res 2014;38:161–6.
Lee JG, Lee YY, Kim SY, Pyo JS, Yun-Choi HS, Park JT. Platelet antiaggregating
activity of ginsenosides isolated from processed ginseng. Pharmazie 2009;64:902–4.
Zhou Q, Jiang L, Xu C, Luo D, Zeng C, Liu P, Yue M, Liu Y, Xu H, Hu G. Ginse-
noside Rg1 inhibits platelet activation and arterial thrombosis. Thromb Res 2014;133:57–65.
Kuo SC, Teng CM, Lee JC, Ko FN, Chen SC, Wu TS. Antiplatelet components in Panax ginseng. Planta Med 1990;56:164–7.
Teng CM, Kuo SC, Ko FN, Lee JC, Lee LG, Chen SC, Huang TF. Antiplatelet ac-
tions of panaxynol and ginsenosides isolated from ginseng. Biochim Biophys Acta 1989;990:315–20.
Mustard JF, Packham MA. Factors influencing platelet function: adhesion, release, and aggregation. Pharmacol Rev 1970;22:97–187.
Holmsen H. Prostaglandin endoperoxide—thermonix synthesis and dense
granule secretion as positive feedback loops in the propagation of platelet responses during the “basic platelet reaction”. Thromb Haemost 1977;38:1030–41.
Borgdorff P, Tangelder GJ. Migraine: possible role of shear-induced platelet aggregation with serotonin release. Headache 2012;52:1289–318.
Kromer W. Drug treatment of pain. 4. Headache and migraine, drug in-
teractions, contra-indications, use of analgesics in pregnancy and lactation. Fortschr Med 1986;104:771–4 [Article in German].
Jenney E, Vladic A, Cicin-Sain L, Hramilovic D, Banovic M, Balija M, Bilić E, Sucic Z, Vukadin S, Grgicevic D. Platelet serotonin measures in migraine. Headache 2002;42:588–95.
Danese E, Montagnana M, Lippi G. Platelets and migraine. Thromb Res 2014;134:17–22.